A New Molecule to Prevent Contrast-Induced Kidney Injury

Administrating Recombinant Human C1-Esterase-Inhibitor (rhC1INH) before coronary angiography might mitigate contrast induced kidney injury. In addition, it shows a favorable safety profile in populations with multiple comorbidities. 

Una nueva molécula para evitar la nefropatía por contraste

The contrast material used in all our diagnostic tests and therapeutic procedures causes tubular cytotoxicity and ischemia/reperfusion injury. rhC1INH had been effective at mitigating this mechanism in experimental models and was therefore ready to be tested against placebo in humans. 

This study included 77 patients with chronic kidney failure blindly randomized to 50 UI/kg rhC1INH vs placebo in elective angiography procedures.

Primary end point was peak change of urinary neutrophil gelatinase-associated lipocalin within 48 h, a specific marker of kidney injury. 


Read also: ST-Segment Elevation Myocardial Infarction in the Time of COVID-19.


Median peak change of urinary neutrophil gelatinase-associated lipocalin was 4.7 ng/ml for the active branch vs. 22.5 ng/ml for the placebo branch (p=0.038) in the per-protocol population, but not in the modified intention-to-treat analysis or in patients treated with PCI after the angiography. 

The incidence of contrast induced kidney injury as per the classic definition was comparable between both groups. Adverse events at 3 months were also similar. 

Conclusion

Prior administration of the recombinant Human C1-Esterase-Inhibitor could mitigate contrast induced kidney injury. And even though, for now, this has only been shown for a surrogate marker of kidney injury, the safety feature of this new molecule is now clear.

j-acc-cardiovascular-interv-nefroproteccion-estudio-randomizado

Original Title: A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury.

Reference: Anneza Panagiotou et al. J Am Coll Cardiol Intv 2020, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...